tiprankstipranks
Advertisement
Advertisement

AU:NSB Stock Latest News

NeuroScientific Advances StemSmart Crohn’s Program After Promising Patient Results
Company AnnouncementsNeuroScientific Advances StemSmart Crohn’s Program After Promising Patient Results
18d ago
NSB
Neuroscientific Biopharmaceuticals Options Expire Unexercised, Trimming Equity Overhang
PremiumCompany Announcements
Neuroscientific Biopharmaceuticals Options Expire Unexercised, Trimming Equity Overhang
1M ago
NSB
NeuroScientific Extends Insider Escrow as Major Share Block Set for Release
PremiumCompany Announcements
NeuroScientific Extends Insider Escrow as Major Share Block Set for Release
2M ago
NSB
NeuroScientific Director Converts Performance Shares After SAS Milestone
PremiumCompany Announcements
NeuroScientific Director Converts Performance Shares After SAS Milestone
2M ago
NSB
NeuroScientific Issues New ASX Securities Under Disclosure Exemption
PremiumCompany Announcements
NeuroScientific Issues New ASX Securities Under Disclosure Exemption
2M ago
NSB
Neuroscientific Biopharmaceuticals Seeks ASX Quotation for 57 Million New Shares
PremiumCompany AnnouncementsNeuroscientific Biopharmaceuticals Seeks ASX Quotation for 57 Million New Shares
2M ago
NSB
NeuroScientific Biopharmaceuticals outlines stem cell strategy for severe Crohn’s disease
Premium
Company Announcements
NeuroScientific Biopharmaceuticals outlines stem cell strategy for severe Crohn’s disease
3M ago
NSB
NeuroScientific Seeks Trading Halt Ahead of Material Program Results
Premium
Company Announcements
NeuroScientific Seeks Trading Halt Ahead of Material Program Results
3M ago
NSB
NeuroScientific advances StemSmart cell therapy with strong early Crohn’s data and scale-up plans
PremiumCompany Announcements
NeuroScientific advances StemSmart cell therapy with strong early Crohn’s data and scale-up plans
4M ago
NSB
NeuroScientific scales up StemSmart manufacturing with Q-Gen for Phase 2 trials
PremiumCompany Announcements
NeuroScientific scales up StemSmart manufacturing with Q-Gen for Phase 2 trials
5M ago
NSB
NeuroScientific Revenue Surges but Half-Year Loss Deepens and Asset Base Shrinks
PremiumCompany Announcements
NeuroScientific Revenue Surges but Half-Year Loss Deepens and Asset Base Shrinks
6M ago
NSB
NeuroScientific Advances StemSmart™ Program as Crohn’s Trial Prep Gathers Pace
PremiumCompany Announcements
NeuroScientific Advances StemSmart™ Program as Crohn’s Trial Prep Gathers Pace
7M ago
NSB
NeuroScientific’s StemSmart Therapy Delivers Strong Results in Fistulising Crohn’s Patients
PremiumCompany AnnouncementsNeuroScientific’s StemSmart Therapy Delivers Strong Results in Fistulising Crohn’s Patients
7M ago
NSB
NeuroScientific Biopharmaceuticals Advances Therapeutics for Crohn’s Disease and Neuroprotection
Premium
Company Announcements
NeuroScientific Biopharmaceuticals Advances Therapeutics for Crohn’s Disease and Neuroprotection
9M ago
NSB
NeuroScientific Biopharmaceuticals to Host Investor Webinar on Strategic Advances
Premium
Company Announcements
NeuroScientific Biopharmaceuticals to Host Investor Webinar on Strategic Advances
9M ago
NSB
NeuroScientific Advances StemSmart™ Therapy for Crohn’s Disease
PremiumCompany Announcements
NeuroScientific Advances StemSmart™ Therapy for Crohn’s Disease
9M ago
NSB
NeuroScientific Biopharmaceuticals Establishes Advisory Board to Drive Innovation
PremiumCompany Announcements
NeuroScientific Biopharmaceuticals Establishes Advisory Board to Drive Innovation
9M ago
NSB
NeuroScientific Biopharmaceuticals Advances StemSmart™ for Crohn’s Disease with Strategic Appointments and Partnerships
PremiumCompany Announcements
NeuroScientific Biopharmaceuticals Advances StemSmart™ for Crohn’s Disease with Strategic Appointments and Partnerships
10M ago
NSB
Neuroscientific Biopharmaceuticals Expands Manufacturing and Proves Clinical Efficacy
PremiumCompany Announcements
Neuroscientific Biopharmaceuticals Expands Manufacturing and Proves Clinical Efficacy
10M ago
NSB
NeuroScientific’s StemSmart™ Gains TGA Approval for Crohn’s Disease Treatment
PremiumCompany AnnouncementsNeuroScientific’s StemSmart™ Gains TGA Approval for Crohn’s Disease Treatment
10M ago
NSB
NeuroScientific Biopharmaceuticals Announces Annual General Meeting Details
Premium
Company Announcements
NeuroScientific Biopharmaceuticals Announces Annual General Meeting Details
11M ago
NSB
NeuroScientific Biopharmaceuticals Announces Annual General Meeting
Premium
Company Announcements
NeuroScientific Biopharmaceuticals Announces Annual General Meeting
11M ago
NSB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >